Introduction: The Unmet Need in High-Risk NMIBC
For decades, intravesical Bacillus Calmette-Guérin (BCG) therapy has remained the undisputed gold standard for patients with high-risk non-muscle-invasive bladder cancer (NMIBC) following transurethral resection of bladder tumor (TURBT). While highly effective in the short term, the clinical reality remains sobering: approximately 40% of patients experience disease recurrence or progression within the first two years of treatment. For these patients, the prognosis is often unfavorable, and the limited availability of bladder-sparing therapeutic options frequently necessitates radical cystectomy, a procedure associated with significant morbidity and quality-of-life impact.
In the era of precision medicine, the success of immune checkpoint inhibitors (ICIs) in metastatic urothelial carcinoma has naturally led to their investigation in the NMIBC setting. The biological rationale is compelling: BCG induces a local inflammatory response that upregulates PD-L1 expression, potentially creating a synergistic environment for PD-(L)1 blockade. This article synthesizes evidence from three landmark Phase 3 trials—POTOMAC, CREST, and ALBAN—to evaluate whether the addition of ICIs to BCG can finally break the therapeutic plateau in high-risk NMIBC.
